(Q36723853)

15 August 2017

1 reference

title

Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? (English)

1 reference

15 August 2017

1 reference

1 reference

1 reference

Miguel Goicoechea

1

1 reference

15 August 2017

Brookie Best

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

8

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

371-382

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Efavirenz liquid formulation in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondri

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Renal safety of tenofovir in HIV treatment-experienced patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Limitations of creatinine as a filtration marker in glomerulopathic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Renal tubular transporters and antiviral drugs: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Mechanism of active renal tubular efflux of tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Neuropsychiatric complications of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

HIV-1 drug resistance in newly infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Is "once-daily" regimen a key strategy for improving adherence to antiretroviral regimens?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.371

21 January 2018

Identifiers

DOI

10.1517/14656566.8.3.371

1 reference

15 August 2017

1 reference